Fusion Antibodies PLC Cash Flow Reinvestment Rate
Fusion Antibodies PLC cash flow reinvestment rate. Fusion Antibodies PLC (FAB) has a Cash Flow Reinvestment Rate of 0.39x as of March 2022, reinvesting GBX67.00K (capex GBX67.00K ) from operating cash flow of GBX174.00K. Explore cash flow to debt ratio of Fusion Antibodies PLC to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Fusion Antibodies PLC (2016–2018)
Cash flow reinvestment rate of Fusion Antibodies PLC from 2016 to 2018. Historical reinvestment intensity for Fusion Antibodies PLC across 2 annual periods. Explore reinvestment intensity of Fusion Antibodies PLC to see what proportion of operating cash flow is directed to capital expenditures.
Fusion Antibodies PLC Cash Flow Reinvestment Rate by Year (2016–2018)
Fusion Antibodies PLC cash flow reinvestment rate by year from 2016 to 2018. Year-by-year capital reinvestment analysis for Fusion Antibodies PLC. For the full cash flow conversion analysis, see FAB cash flow metrics.
| Year | Reinvestment Rate | Total Reinvested (GBX) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2018 | 11.52x | GBX889.19K | GBX77.19K | GBX444.60K | ▲ +11063.6% |
| 2016 | 0.10x | GBX35.76K | GBX346.57K | GBX35.76K | — |